Clinical trial NCT01370239: HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy
Official title: A Multicenter Phase II Study of Treatment With Hu3S193 in Women With Advanced Breast Cancer That Progressed After Hormonal Therapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Breast Cancer
Keywords: monoclonal antibody
Lewis
breast cancer
Lead sponsor: Instituto do Cancer do Estado de São Paulo
Sponsor class: OTHER
Collaborators: name: Fundação Faculdade de Medicina
name: Recepta Biopharma
First posted: 2011-06-09
Enrollment: 23
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The humanized monoclonal antibody against Lewis Y antigen (Hu3S193) has been demonstrated to be safe in previous studies and has also been indicated as potential intervention in breast cancer. The study of this new agent in advanced breast cancer may contribute to the development of new strategies for patients that progressed after hormonal treatment.

Detailed description: This is a national study, open label, single arm, phase II study which will be conducted in seven centers in Brazil. The study will be coordinated by the INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO in collaboration with RECEPTA Biopharma. The study is funded by the CONSELHO NACIONAL DE DESENVOLVIMENTO CIENTÍFICO E TECNOLÓGICO (CNPq). Before any procedure relating to the study, patients must read and sign the informed consent (IC). The inclusion of patients begin immediately after regulatory approval and is expected to end after reaching the number of patients. The follow-up term will last at least 24 months for each patient included, unless limited by death, loss to follow up or withdrawal of informed consent. A total of 60 patients will be recruited in this study. The eligible patients must be 18 or older, confirmed diagnosis of breast cancer with locally advanced or metastatic progression after one or two lines of previous hormone treatment, confirmation of Lewis antigen expression -as assessed by central laboratory, measurable or evaluable disease and adequate organ function. Patients will receive weekly intravenous doses of the antibody Hu3S193 until disease progression, unacceptable toxicity, withdrawal of consent or the investigator's decision, whichever occurs first. The study's primary endpoint is the clinical benefit rate.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of breast cancer with locally advanced or metastatic (stages IIIB, IIIC or IV according to TNM classification), confirmed histologically with no intention to curative treatment by radiotherapy or surgery;
* Clinical or radiological progression after one or two lines of previous hormone treatment, including adjuvant treatment;
* Positive for ER and / or PR expression documented by IHC;
* Confirmed expression of Lewis Y antigen by IHC;
* Presenting the performance status of 0 or 1 according to Eastern Cooperative Oncology Group (ECOG);
* Have a measurable or evaluable disease by Response of Evaluation Criteria in Solid Tumors (RECIST);
* Adequate organ function, assessed by laboratory tests obtained at least 2 weeks before the first day of treatment and within the following parameters:

absolute neutrophil count ≥ 1.5 x 109 / L; platelet count ≥ 100 x 109 / L; serum bilirubin ≤ 2.0 mg / dL; AST/ALT ≤ 2.5 x upper limit of normal; serum creatinine ≤ 2.0 mg / dL;

* Expected survival \> 12 weeks;
* In patients with childbearing potential: Negative pregnancy confirmed by test done 21 days before the date of study treatment initiation;
* Willingness and ability to comply with the protocol for the duration of the study.

Exclusion Criteria:

* Patients subjected previously to more than two lines of hormonal therapy, including adjuvant treatment;
* Presenting the amplification or overexpression of HER-2;
* Systemic corticosteroids or immunosuppressive agents used concomitantly with the study or have used systemic corticosteroids or immunosuppressants in the last 14 days before the first dose of the investigational drug;
* Visceral metastatic disease with life-threatening (as defined by extensive liver involvement), or symptomatic pulmonary lymphangitic carcinomatosis or any degree of cerebral or leptomeningeal involvement;
* Previous or current history of clinically significant cardiac disease (class III or IV according to New York Heart Association);
* Clinically significant arrhythmia;
* History of myocardial infarction within the last 6 months;
* Previous or current history of other severe diseases (eg, severe ascites requiring repeated drainage, active infections requiring antibiotics, bleeding, inflammatory bowel disease or chronic diseases that may interfere with obtaining accurate results of the study);
* Previous chemotherapy for metastatic disease (adjuvant chemotherapy is acceptable, if more than four weeks between its completion and inclusion in the study;
* Radiotherapy within 4 weeks before inclusion in the study or with no recovery from the toxic effects of radiotherapy when done up to 6 weeks before inclusion in the study, except for palliative radiotherapy for bone metastases involving \<25 % bone marrow;
* Treatment with biological agents, immunotherapy or surgery within 4 weeks before inclusion in the study or with no recovery from the toxic effects of these treatments when made until six weeks prior to study entry (prior treatment with bisphosphonates is allowed, it can be continued after inclusion in the study);
* Any investigational agent treatment within 12 months prior to study entry, unless the investigator considers that the participation in the study may benefit the patient;
* Previous or current history of another type of tumor, excluding skin cancer, melanoma, in situ cervix carcinoma or in situ ductal carcinoma or lobular breast if properly treated;
* Uncontrolled hypercalcemia (defined as total calcium\> 11.5 mg / dL)

Primary outcomes:
measure: Complete response, partial response or stable disease.
timeFrame: more than 24 weeks
Secondary outcomes:
measure: Response rate
timeFrame: 24 weeks after patient discontinuation (at minimum)
measure: Non progression rate
timeFrame: 24 weeks after patient discontinuation (at minimum)
measure: Overall survival
timeFrame: 24 weeks after patient discontinuation (at minimum) or until death
measure: Progression free survival
timeFrame: until disease progression or 24 weeks after patient discontinuation (at minimum)
measure: Assessment of any sign, symptom or undesirable medical condition that occurs after the first administration of the investigational agent
timeFrame: Until disease progression or 30 days after patient discontinuation
Other outcomes:
Locations:
city: Fortaleza
country: Brazil
facility: Universidade Federal Do Ceará
state: Ceará
city: Porto Alegre
country: Brazil
facility: PONTIFíCIA UNIVERSIDADE CATÓLICA DO RIO GRANDE DO SUL
state: RIO Grande DO SUL
city: Barretos
country: Brazil
facility: Hospital Do Câncer de Barretos
state: SÃO Paulo
city: Goias
country: Brazil
facility: Universidade Federal de Goias
city: Rio de Janeiro
country: Brazil
facility: Instituto Nacional Do Câncer
city: Sao Paulo
country: Brazil
facility: Instituto Do Câncer Do Estado de São Paulo
city: Sao Paulo
country: Brazil
facility: Hospital Sirio Libanes
Study officials:
affiliation: INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO
name: PAULO MG HOFF, MD Professor
role: STUDY_DIRECTOR
affiliation: HOSPITAL DO CÂNCER DE BARRETOS
name: SERGIO V SERRANO, MD
role: STUDY_DIRECTOR
References:
citation: Testa L, Mano M, Arai RJ, Bonadio RC, Serrano SV, Zorzetto MMC, Crocamo S, Smaletz O, Freitas-Junior R, Hoff PM. Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy. Clinics (Sao Paulo). 2021 Oct 11;76:e3146. doi: 10.6061/clinics/2021/e3146. eCollection 2021.